Literature DB >> 34227057

Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia.

Qiongqiong Wu1, Xiaoyi Wang1, Ying Wang1, Yu-Jun Long1, Jing-Ping Zhao2, Ren-Rong Wu3,4.   

Abstract

The causal mechanisms and treatment for the negative symptoms and cognitive dysfunction in schizophrenia are the main issues attracting the attention of psychiatrists over the last decade. The first part of this review summarizes the pathogenesis of schizophrenia, especially the negative symptoms and cognitive dysfunction from the perspectives of genetics and epigenetics. The second part describes the novel medications and several advanced physical therapies (e.g., transcranial magnetic stimulation and transcranial direct current stimulation) for the negative symptoms and cognitive dysfunction that will optimize the therapeutic strategy for patients with schizophrenia in future.

Entities:  

Keywords:  Cognitive dysfunction; Epigenetics; Genetics; Negative symptoms; Physical therapy; Schizophrenia

Year:  2021        PMID： 34227057     DOI： 10.1007/s12264-021-00740-6

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN： 1995-8218            Impact factor:   5.203


  187 in total

Review 1.  Negative symptoms in schizophrenia: a review.

Authors:  J Mäkinen; J Miettunen; M Isohanni; H Koponen
Journal:  Nord J Psychiatry       Date:  2008       Impact factor: 2.202

2.  Flat affect and social functioning: a 10 year follow-up study of first episode psychosis patients.

Authors:  Julie Evensen; Jan Ivar Røssberg; Helene Barder; Ulrik Haahr; Wenche Ten Velden Hegelstad; Inge Joa; Jan Olav Johannessen; T K Larsen; Ingrid Melle; Stein Opjordsmoen; Bjørn Rishovd Rund; Erik Simonsen; Per Vaglum; Thomas McGlashan; Svein Friis
Journal:  Schizophr Res       Date:  2012-05-23       Impact factor: 4.939

3.  Neurocognition and Duration of Psychosis: A 10-year Follow-up of First-Episode Patients.

Authors:  Bjørn Rishovd Rund; Helene Eidsmo Barder; Julie Evensen; Ulrik Haahr; Wenche ten Velden Hegelstad; Inge Joa; Jan Olav Johannessen; Johannes Langeveld; Tor Ketil Larsen; Ingrid Melle; Stein Opjordsmoen; Jan Ivar Røssberg; Erik Simonsen; Kjetil Sundet; Per Vaglum; Thomas McGlashan; Svein Friis
Journal:  Schizophr Bull       Date:  2015-06-21       Impact factor: 9.306

4.  Systematic meta-analysis of childhood social withdrawal in schizophrenia, and comparison with data from at-risk children aged 9-14 years.

Authors:  Sandra L Matheson; Hena Vijayan; Hannah Dickson; Alana M Shepherd; Vaughan J Carr; Kristin R Laurens
Journal:  J Psychiatr Res       Date:  2013-04-28       Impact factor: 4.791

5.  Social anhedonia as a predictor of the development of schizophrenia-spectrum disorders.

Authors:  T R Kwapil
Journal:  J Abnorm Psychol       Date:  1998-11

6.  Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis.

Authors:  Jonathan Rabinowitz; Carmen Galani Berardo; Dragana Bugarski-Kirola; Stephen Marder
Journal:  Schizophr Res       Date:  2013-07-27       Impact factor: 4.939

Review 7.  Development of social functioning in preschizophrenia children and adolescents: a systematic review.

Authors:  Sarah I Tarbox; Michael F Pogue-Geile
Journal:  Psychol Bull       Date:  2008-07       Impact factor: 17.737

8.  Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10year follow-up study in the OPUS cohort.

Authors:  Stephen F Austin; Ole Mors; Esben Budtz-Jørgensen; Rikke Gry Secher; Carsten R Hjorthøj; Mette Bertelsen; Pia Jeppesen; Lone Petersen; Anne Thorup; Merete Nordentoft
Journal:  Schizophr Res       Date:  2015-08-08       Impact factor: 4.939

9.  Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study.

Authors:  Antoni Sicras-Mainar; Jorge Maurino; Elena Ruiz-Beato; Ruth Navarro-Artieda
Journal:  BMC Psychiatry       Date:  2014-08-06       Impact factor: 3.630

Review 10.  Schizophrenia.

Authors:  Michael J Owen; Akira Sawa; Preben B Mortensen
Journal:  Lancet       Date:  2016-01-15       Impact factor: 79.321
View more
  5 in total

1.  A Critical Role for γCaMKII in Decoding NMDA Signaling to Regulate AMPA Receptors in Putative Inhibitory Interneurons.

Authors:  Xingzhi He; Yang Wang; Guangjun Zhou; Jing Yang; Jiarui Li; Tao Li; Hailan Hu; Huan Ma
Journal:  Neurosci Bull       Date:  2022-03-15       Impact factor: 5.271

Review 2.  Sodium Benzoate-Harmfulness and Potential Use in Therapies for Disorders Related to the Nervous System: A Review.

Authors:  Łucja Justyna Walczak-Nowicka; Mariola Herbet
Journal:  Nutrients       Date:  2022-04-02       Impact factor: 5.717

3.  Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia.

Authors:  Olga Yu Fedorenko; Diana Z Paderina; Elena G Kornetova; Evgeniya G Poltavskaya; Ivan V Pozhidaev; Anastasiia A Goncharova; Maxim B Freidin; Anna V Bocharova; Nikolay A Bokhan; Anton J M Loonen; Svetlana A Ivanova
Journal:  Diagnostics (Basel)       Date:  2022-06-22

Review 4.  The effects and mechanism of environmental enrichment on MK-801 induced cognitive impairment in rodents with schizophrenia.

Authors:  Jinwei Xu; Yaohao Li; Biqing Tian; Haiying Liu; Shengxi Wu; Wenting Wang
Journal:  Front Cell Neurosci       Date:  2022-09-29       Impact factor: 6.147

5.  Transcranial direct current stimulation of the occipital lobes with adjunct lithium attenuates the progression of cognitive impairment in patients with first episode schizophrenia.

Authors:  Chuanjun Zhuo; Hongjun Tian; Chunhua Zhou; Yun Sun; Xinying Chen; Ranli Li; Jiayue Chen; Lei Yang; Qianchen Li; Qiuyu Zhang; Yong Xu; Xueqin Song
Journal:  Front Psychiatry       Date:  2022-09-13       Impact factor: 5.435
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.